Dossier assessment
Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Report documents
-
Extract of dossier assessment
Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
-
Dossier assessment
Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Dossier assessment
Primary hypercholesterolaemia or mixed dyslipidaemia
Added benefit neither proven for patients for whom statin therapy is an option nor for patients with intolerance or contraindication to statin therapy
Additional information
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.
Project details
- Project no.
- A18-74
- Commission
- Commission awarded on 31.10.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Alirocumab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed